Lv4
640 积分 2024-10-31 加入
The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC
5个月前
已完结
Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models
5个月前
已完结
The paths toward immunotherapy of esophageal cancer: An overview of clinical trials
6个月前
已完结
Efficient Biomarker for Immunotherapy: Measuring Broad Clones Effector Tumor Antigen-Specific T Cells in the Blood of Esophageal Cancer Patients
6个月前
已完结
Oesophageal cancer
6个月前
已完结
Discovery of Potent and Selective CDK4/6 Inhibitors for the Treatment of Chemotherapy-Induced Myelosuppression
8个月前
已完结
New Drug Protects Against Myelosuppression Secondary to Lung Cancer Chemotherapy
8个月前
已完结
Oesophageal cancer
9个月前
已完结
Emerging role and clinical applications of circular RNAs in human diseases
1年前
已完结
皖公网安备34019202002308
